naltrexone has been researched along with Suicidal Ideation in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Bentzley, BS; Blasey, C; Hawkins, J; Heifets, BD; Lyons, DM; Schatzberg, AF; Sudheimer, KD; Williams, NR | 1 |
GarcĂa, MC | 1 |
Binswanger, IA; Fazel, S; Hellner, C; Larsson, H; Molero, Y; Zetterqvist, J | 1 |
1 review(s) available for naltrexone and Suicidal Ideation
Article | Year |
---|---|
[Treatment of borderline personality disorder with opioid antagonists: buprenorphine, nalmefene, naloxone and naltrexone in the treatment of dissociative symptoms, self-mutilation and suicidal behavior].
Topics: Borderline Personality Disorder; Buprenorphine; Dissociative Disorders; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Observational Studies as Topic; Self Mutilation; Suicidal Ideation | 2020 |
3 other study(ies) available for naltrexone and Suicidal Ideation
Article | Year |
---|---|
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Receptors, Opioid; Suicidal Ideation; Suicide; Treatment Outcome | 2019 |
Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Cohort Studies; Crime; Drug Overdose; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Factors; Suicidal Ideation; Young Adult | 2018 |
New obesity pill: new hopes, old fears.
Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Approval; Drug Combinations; Exercise; Feeding Behavior; Humans; Life Style; Naltrexone; Narcotic Antagonists; Obesity; Seizures; Suicidal Ideation; United States; United States Food and Drug Administration | 2010 |